| Author | Papot, Emmanuelle | |
| Author | Tovar-Sanchez, Tamara | |
| Author | Woods, Joana | |
| Author | Thaurignac, Guillaume | |
| Author | ERIOBU, Nnakelu | |
| Author | Borok, Margaret | |
| Author | Kaplan, Richard | |
| Author | Avihingsanon, Anchalee | |
| Author | Azwa, Iskandar | |
| Author | Grinsztejng, Beatriz | |
| Author | Kumarasamy, Nagalingeswaran | |
| Author | Sokhela, Simiso | |
| Author | Mpoudi-Etame, Mireille | |
| Author | Arriaga, Maria | |
| Author | Jacoby, Simone | |
| Author | Matthews, Gail V. | |
| Author | Losso, Marcelo H. | |
| Author | Khoo, Saye | |
| Author | Calmy, Alexandra | |
| Author | Kouanfack, Charles | |
| Author | Ayouba, Ahidjo | |
| Author | Petoumenos, Kathy | |
| Author | Venter, W.D. Francois | |
| Author | Delaporte, Eric | |
| Author | Polizzotto, Mark N. | |
| Access date | 2025-03-01T23:23:57Z | |
| Available date | 2025-03-01T23:23:57Z | |
| Document date | 2024 | |
| Citation | PAPOT, Emmanuelle et al. SARS-CoV-2 cross-sectional serosurvey across three HIV-1 therapeutic clinical trials in Africa. AIDS, p. 1-20, Nov. 2024. | |
| ISSN | 0269-9370 | |
| URI | https://www.arca.fiocruz.br/handle/icict/68778 | |
| Description | On behalf of COHIVE study group (COHIVE consortium includes ADVANCE, DolPHIN2, D2EFT and NAMSAL study groups). | en_US |
| Sponsorship | Funding for DolPHIN2 study was provided by Unitaid, with dolutegravir donated by ViiV Healthcare. | |
| Language | eng | en_US |
| Publisher | Lippincott Williams & Wilkins | |
| Later version | https://www.arca.fiocruz.br/handle/icict/69101 | |
| Rights | open access | |
| Title | SARS-CoV-2 cross-sectional serosurvey across three HIV-1 therapeutic clinical trials in Africa | en_US |
| Type | Preprint | |
| DOI | 10.1097/QAD.0000000000004068 | |
| Abstract | Objective: Data on the impact of COVID-19 in people living with HIV (PWH) are lacking in resource-constrained settings. We utilised existingrandomised clinical trials (RCTs) on antiretroviral therapies (ART) in HIV-1 infection to conduct a SARS-CoV-2 serosurvey, between January and March 2021, while characterising participants' features. Design: Cross-sectional serosurvey. Methods: Demographic characteristics, medical history and a serum sample were collected from consenting PWH. Samples were analysed centrally for immunoglobulin G antibodies to recombinant nucleocapsid and spike proteins derived from SARS-CoV-2 using a Luminex based assay. Results: The 549participants recruited in 9 sites across Africa had a median age of 40 years (IQR [34-45]); 63.0% (346) were female. All were on ART; 81.8% (449) had an HIV-1 viral load <50 copies/mL, with CD4 count median at 478/mm 3 (IQR [320-677]). None had received vaccination against SARS-CoV-2. Forty participants (7.3%) had a prior SARS-CoV-2 PCR testing, of whom 10 were positive (1.8%). Crude SARS-CoV-2 seroprevalence was 36.2% (; 95%CI [32.2-40.4]). In the explorative multivariable analysis, comparison of the characteristics of PWH with a positive SARS-CoV-2 serology with those with a negative or indeterminate serology: PWH with a body mass index (BMI)≥30 kg/m 2 were more likely to have a positive serology than those with a BMI≤25 (aOR = 2.39 [1.48-3.86], p < 0.001); and PWH living in Cameroon were less likely to have a positive serology. Conclusion: This study demonstrates a substantial seroprevalence level of SARS-CoV-2 in PWH in the first quarter of 2021, with a marked disparity with the number of COVID-19 PCR tests reported positive. | en_US |
| Affilliation | University of New South Wales Sydney. The Kirby Institute. Therapeutic and Vaccine Research Program. NSW, Australia. | |
| Affilliation | University of Montpellier-IRD-INSERM. TransVIHMI. Montpellier, France. | |
| Affilliation | University of the Witwatersrand. Faculty of Health Sciences. Ezintsha. Johannesburg, South Africa. | |
| Affilliation | University of Montpellier-IRD-INSERM. TransVIHMI. Montpellier, France. | |
| Affilliation | Institute of Human Virology Nigeria. Abuja, Nigeria. | |
| Affilliation | University of Zimbabwe Clinical Research Centre. Harare, Zimbabwe. | |
| Affilliation | Desmond Tutu Health Foundation. Cape Town, South Africa. | |
| Affilliation | The HIV Netherlands Australia Thailand Research Collaboration. Thai Red Cross AIDS Research Centre. Bangkok, Thailand. | |
| Affilliation | University of Malaya. Faculty of Medicine. Department of Medicine. Infectious Diseases Unit. Kuala Lumpur, Malaysia. | |
| Affilliation | Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Rio de Janeiro, RJ, Brasil. | |
| Affilliation | Chennai Antiviral Research and Treatment Clinical Research Site. Infectious Diseases Medical Centre. Voluntary Health Services. Chennai, India. | |
| Affilliation | University of the Witwatersrand. Faculty of Health Sciences. Ezintsha. Johannesburg, South Africa. | |
| Affilliation | Military Hospital Region N°1. Yaoundé, Cameroon. | |
| Affilliation | University of New South Wales Sydney. The Kirby Institute. Therapeutic and Vaccine Research Program. NSW, Australia. | |
| Affilliation | University of New South Wales Sydney. The Kirby Institute. Therapeutic and Vaccine Research Program. NSW, Australia. | |
| Affilliation | University of New South Wales Sydney. The Kirby Institute. Therapeutic and Vaccine Research Program. NSW, Australia. | |
| Affilliation | Coordinación en Investigación Clínica Académica en Latinoamérica Fundación IBIS. Buenos Aires, Argentina. | |
| Affilliation | Department of Molecular and Clinical Pharmacology University of Liverpool. Liverpool, UK. | |
| Affilliation | Geneva University Hospitals. HIV/AIDS Unit Director. Geneva, Switzerland. | |
| Affilliation | Central Hospital of Yaoundé. Yaoundé, Cameroon. | |
| Affilliation | University of Montpellier-IRD-INSERM. TransVIHMI. Montpellier, France. | |
| Affilliation | University of New South Wales. The Kirby Institute. Biostatistics and Databases Program. Sydney, NSW, Australia. | |
| Affilliation | University of the Witwatersrand. Faculty of Health Sciences. Ezintsha. Johannesburg, South Africa. | |
| Affilliation | University of Montpellier-IRD-INSERM. TransVIHMI. Montpellier, France. | |
| Affilliation | University of New South Wales. The Kirby Institute. Therapeutic and Vaccine Research Program. Sydney, NSW, Australia / The Australian National University. College of Health and Medicine. Clinical Hub for Interventional Research. Australia. | |
| Subject | Coronavirus disease 2019 | en_US |
| Subject | People with HIV | en_US |
| Subject | Randomized clinical trials | en_US |
| Subject | Serology | en_US |
| e-ISSN | 1473-5571 | |
